Prophylaxis against early ventilator-associated infections to reduce mortality in mechanically ventilated ICU patients with acute brain injuries (NCT06819592)

The PREVENT-NEURO study will test the hypothesis that among adults with acute brain injuries receiving invasive mechanical ventilation in the ICU (participants), one dose of 2g of intravenous ceftriaxone administered as soon as practical after endotracheal intubation (intervention), compared to a matched placebo (comparator), reduces 90-day mortality (primary outcome).

Trial phase

Phase 3

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Prof Andrew Udy

Key inclusion data

INCLUSION: Adult patients receiving invasive mechanical ventilation due to an acute brain injury (intracranial haemorrhage, ischaemic stroke, cerebral venous sinus thrombosis, subarachnoid haemorrhage, suspected hypoxic ischaemic encephalopathy post cardiac arrest, or traumatic brain injury), and admitted to an ICU. EXCLUSION: Endotracheal intubation more than 12 hours ago; hospital admission more than 72 hours ago; inability to deliver trial intervention within 90 minutes of randomisation; Documented us of antibiotics in the week prior to hospitalisation or anticipated need for ongoing antibiotic therapy; contraindication to ceftriaxone; death within 90 days inevitable.